Our vision is to contribute to the identification of new therapeutic tools for the prevention and treatment of acute renal failure and sepsis, and to reduce mortality rates that have remained unchanged for more than 50 years.
We are guided by values of professionalism, responsibility, honesty, tenacity, perseverance, efficiency, respect, and sensitivity.
Telara pharma's mission is to bring to clinical use the first kidney-protective drug to prevent and treat sepsis and septic and toxic acute renal failure, improve patients' quality of life, reduce their hospital stay and help save lives.
Why do we do what we do?
Acute kidney Injury (AKI) is a syndrome that results in a sudden decrease in kidney function and currently is one of the most serious and common health problems in the world associated with severe morbidity and mortality as well as the development of chronic kidney disease (CKD).
Every year, it affects around 13.3 million people, causing 1,7 million deaths. It therefore represents a true epidemic in today's nephrology where 1 in 5 adults and 1 in 3 children worldwide experience AKI during a hospital episode of care with a mortality rate of 50-80%.
Early treatment of AKI is one of the best maneuvers to limit damage, but unfortunately, there is still no approved drug therapy for this indication.
Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón Universitary General Hospital focused and committed to kidney disease improvement. We are developing a new therapeutic strategy for the treatment of acute kidney injury induced by toxics, sepsis, and sepsis-included acute kidney failure.
We are currently supported by: